Abstract
Objective: In precision medicine, the concept of individually treating cancer patients has been recently emphasized. In trying to find treatments, patient-derived tumor xenografts (PDX) models have been used. We identified the stability of PDXs of uterine cancer and the preclinical efficacy for targeted treatment in specific uterine cancers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
